Sun Pharma-owned subsidiary to acquire Canada's Aquinox Pharma for $8.2 mn
Indian company says no approvals are required for the acquisition and it is likely to be completed by July 3129-07-2020
29-07-2020
SUN PHARMACEUTICAL INDUSTRIES LTD. - 524715 - Announcement under Regulation 30 (LODR)-Acquisition
This is to inform you that one of the wholly owned subsidiaries of our subsidiary company, Taro Pharmaceutical Industries Ltd., has agreed to acquire by way of purchase of all outstanding shares of Aquinox Pharmaceuticals (Canada) Inc., a corporation organized and existing under the laws of the Province of British Columbia that carries on the business of research and development of pharmaceutical products for purposes of their commercialization. The disclosures pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and Part A of Schedule III of the aforesaid regulations, are attached as per 'Annexure A'. This is for your information and record.29-07-2020
SUN PHARMACEUTICAL INDUSTRIES LTD. - 524715 - Notice Of Book Closure And Details Of 28Th Annual General Meeting Of The Company For The Financial Year Ended March 31, 2020.
This is to inform you that the 28th Annual General Meeting of the shareholders of the Company would be held on Thursday, August 27, 2020 at 03:30 p.m. IST through Video Conferencing / Other Audio-Visual Means ('28th AGM'). Further, in accordance with Regulation 42 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby inform you that the Register of Members and Share Transfer Books of the Company will remain closed from Friday, August 21, 2020 till Thursday, August 27, 2020 (both days inclusive) for the purpose of holding of the 28th AGM and declaration and payment of final dividend for the financial year ended March 31, 2020, subject to approval of the shareholders, at the 28th AGM.28-07-2020
Sun Pharma arm Taro resolves US antitrust cases
Taro Pharmaceuticals USA was part of five of six companies that were part of the DOJ's investigation into price fixing, market allocation, bid rigging, and other anticompetitive conduct in the generic pharmaceutical industry24-07-2020
SUN PHARMACEUTICAL INDUSTRIES LTD. - 524715 - Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011.
The Exchange has received Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 on July 24, 2020 for Shanghvi Finance Pvt Ltd24-07-2020
Sun Pharma, Trent: 10 stocks that look bullish on moving average indicator
The most widely used, the 200 DMA, is a technical indicator used to analyse and identify long term trends24-07-2020
SUN PHARMACEUTICAL INDUSTRIES LTD. - 524715 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Press Release of our subsidiary company relating to global resolution of DOJ antitrust investigations24-07-2020
SUN PHARMACEUTICAL INDUSTRIES LTD. - 524715 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Press Release relating to announcement of financial results for the first quarter ending June 30, 2020, which we shall be releasing after sending this letter to you. This is for your information and record. Thanking you,23-07-2020
SUN PHARMACEUTICAL INDUSTRIES LTD. - 524715 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Press Release relating to announcement of financial results for the first quarter ending June 30, 2020, which we shall be releasing after sending this letter to you. This is for your information and record. Thanking you,23-07-2020
SUN PHARMACEUTICAL INDUSTRIES LTD. - 524715 - Board Meeting Intimation for To Consider And Approve Unaudited Standalone And Consolidated Financial Results Of The Company For The Quarter Ended June 30, 2020
SUN PHARMACEUTICAL INDUSTRIES LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 31/07/2020 ,inter alia, to consider and approve This is to inform you that the meeting of the Board of Directors of the Company will be held on Friday, July 31, 2020, interalia, to consider and approve Unaudited Standalone and Consolidated Financial Results of the Company for the quarter ended June 30, 2020. Further, kindly note that pursuant to the Company''s Code of Conduct for Prevention of Insider Trading, the window closure for trading by Designated Persons, commenced on July 01, 2020, and shall end on August 02, 2020.22-07-2020